---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-03T11:28:17.225599'
end_time: '2026-06-03T11:40:19.280222'
duration_seconds: 722.05
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AKIRIN1
  gene_symbol: AKIRIN1
  uniprot_accession: Q9H9L7
  protein_description: 'RecName: Full=Akirin-1 {ECO:0000305};'
  gene_info: Name=AKIRIN1 {ECO:0000303|PubMed:18066067, ECO:0000312|HGNC:HGNC:25744};
    Synonyms=C1orf108 {ECO:0000312|HGNC:HGNC:25744};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the akirin family.
  protein_domains: Akirin. (IPR024132)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 30
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: AKIRIN1-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H9L7
- **Protein Description:** RecName: Full=Akirin-1 {ECO:0000305};
- **Gene Information:** Name=AKIRIN1 {ECO:0000303|PubMed:18066067, ECO:0000312|HGNC:HGNC:25744}; Synonyms=C1orf108 {ECO:0000312|HGNC:HGNC:25744};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the akirin family.
- **Key Domains:** Akirin. (IPR024132)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AKIRIN1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AKIRIN1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AKIRIN1** (gene ID: AKIRIN1, UniProt: Q9H9L7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H9L7
- **Protein Description:** RecName: Full=Akirin-1 {ECO:0000305};
- **Gene Information:** Name=AKIRIN1 {ECO:0000303|PubMed:18066067, ECO:0000312|HGNC:HGNC:25744}; Synonyms=C1orf108 {ECO:0000312|HGNC:HGNC:25744};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the akirin family.
- **Key Domains:** Akirin. (IPR024132)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AKIRIN1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AKIRIN1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AKIRIN1** (gene ID: AKIRIN1, UniProt: Q9H9L7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Research Report: Human **AKIRIN1** (UniProt **Q9H9L7**; “Akirin-1/Mighty”) — functional annotation

### 0) Target verification (critical gene/protein identity)
The target in this report is **human AKIRIN1** (UniProt accession **Q9H9L7**), encoding **Akirin-1** (historically termed **“Mighty”** in the muscle field), a member of the conserved **akirin family** of small nuclear proteins. Authoritative reviews describe mammalian Akirin proteins as ~200 aa (~22 kDa) nuclear factors with a conserved N-terminal **nuclear localization signal (NLS)**, lacking obvious catalytic domains—supporting classification as a **non-enzymatic transcriptional cofactor/adaptor** rather than an enzyme or transporter. (https://doi.org/10.1007/s00018-020-03531-w; published 2020-05) (bosch2020akirinproteinsin pages 1-3, bosch2020akirinproteinsin pages 3-4). AKIRIN1 is distinct from **AKIRIN2**, which is more often essential in development; Akirin1-null mice are reported as viable/outwardly normal in review summaries, indicating paralog divergence. (bosch2020akirinproteinsin pages 1-3)

### 1) Key concepts and current understanding (definitions, mechanistic model)
#### 1.1 What AKIRIN1 is (conceptual definition)
Akirin proteins are best understood as **context-dependent transcriptional cofactors** that help couple sequence-specific transcriptional regulators to **chromatin remodeling** and promoter selection. Reviews emphasize that akirins are highly conserved and largely **intrinsically disordered**, with minimal recognizable domains, consistent with a role as a “bridge” or scaffold for protein–protein interactions rather than a catalytic function. (https://doi.org/10.1007/s00018-020-03531-w; 2020-05) (bosch2020akirinproteinsin pages 1-3, bosch2020akirinproteinsin pages 15-15). A complementary review (developmental context) similarly frames Akirin as a secondary cofactor linking transcription factors to SWI/SNF-class chromatin remodeling complexes while noting that direct DNA-binding has not been clearly established. (https://doi.org/10.4161/bioa.22907; 2012-11) (nowak2012akirin pages 1-2)

#### 1.2 Subcellular localization
Across species and in vertebrates, Akirin proteins show **predominantly nuclear localization**, consistent with roles at promoters/enhancers. Bosch et al. highlight strong nuclear localization across species while also noting that some non-nuclear protein can be observed and that clear cytoplasmic functions are not yet established. (bosch2020akirinproteinsin pages 4-6)

#### 1.3 Family-level mechanism: bridging transcription factors to SWI/SNF chromatin remodeling
Although some of the most detailed mechanistic dissection is for Akirin2 or in Drosophila, the **core mechanistic concept** is conserved: akirins provide **transcriptional selectivity** by enabling recruitment or stabilization of **SWI/SNF (BAF/Brahma)** remodeling complexes at only a subset of inducible genes.

In Drosophila innate immunity, Akirin acts as an NF-κB (Relish) cofactor required for expression of a **subset** of Relish-dependent genes; genome-wide expression analysis reported Relish required for **170** induced genes after immune challenge, of which **17** were also Akirin-dependent, and Akirin alone was required for **31** genes independent of Relish—supporting a selector/cofactor model. (https://doi.org/10.15252/embj.201488456; 2014-09) (bonnay2014akirinspecifiesnfκb pages 1-2). Proteomics and co-IP data further linked Akirin to SWI/SNF-like Brahma complex components (e.g., BAP60) and stimulus-enhanced association with Relish. (bonnay2014akirinspecifiesnfκb pages 3-5)

In vertebrates/mammals, reviews synthesize evidence that Akirin2 forms complexes with **IκBζ** and **BAF60** isoforms to promote inflammatory gene transcription (e.g., IL-6) through recruitment of SWI/SNF core machinery (Brg1). (bosch2020akirinproteinsin pages 3-4, bosch2020akirinproteinsin pages 7-8)

### 2) AKIRIN1 primary biological function (human/mammalian evidence emphasized)
#### 2.1 AKIRIN1 in skeletal muscle: promyogenic gene regulatory factor (non-enzymatic)
The strongest AKIRIN1-specific mechanistic evidence in the retrieved corpus concerns skeletal muscle biology, where AKIRIN1/Mighty functions as a **promyogenic nuclear factor** that supports **myoblast/satellite cell proliferation and differentiation**.

A key primary study in mouse and myogenic cell models (Dong et al., PLoS ONE; 2013-03-13) provides multiple lines of evidence:
- **Glucocorticoids (dexamethasone, Dex)** suppress satellite cell proliferation/differentiation, accompanied by **myostatin induction** and **Akirin1 suppression**. (https://doi.org/10.1371/journal.pone.0058554; 2013-03) (dong2013myostatinsuppressionof pages 1-2, dong2013myostatinsuppressionof pages 3-4)
- **Dex or recombinant myostatin decreases Akirin1 mRNA/protein** in satellite cells; myostatin knockdown/inhibition prevents Dex-mediated Akirin1 suppression and improves proliferation/differentiation even with Dex present. (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 3-4)
- **Akirin1 overexpression** in myoblasts increases myogenic regulators **MyoD** and **myogenin** and improves proliferation/differentiation; these improvements are reported to persist despite Dex treatment. (dong2013myostatinsuppressionof pages 4-8, dong2013myostatinsuppressionof pages 1-2)

Interpretation: these data support AKIRIN1 as a downstream **positive effector** of myogenic gene programs whose expression is **negatively regulated** by myostatin in settings of glucocorticoid stress, positioning AKIRIN1 as part of a regulatory axis relevant to muscle wasting and impaired regeneration. (dong2013myostatinsuppressionof pages 8-11)

#### 2.2 Relationship to myostatin/glucocorticoid pathway (core pathway placement)
The Dong et al. data explicitly argue for the pathway: **glucocorticoid → myostatin upregulation → AKIRIN1 downregulation → satellite cell dysfunction**, with experimental rescue by myostatin inhibition and by AKIRIN1 overexpression. (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 3-4)

#### 2.3 NF-κB / innate immunity linkage: stronger evidence for akirin family/AKIRIN2 than AKIRIN1
In the retrieved material, the most direct mechanistic NF-κB/SWI-SNF bridging evidence is from Drosophila Akirin and mammalian Akirin2-centered work; reviews emphasize akirins as conserved nuclear proteins required for NF-κB-dependent gene expression, but **AKIRIN1-specific** immune phenotyping is less developed in the excerpts here. (bosch2020akirinproteinsin pages 15-15, bonnay2014akirinspecifiesnfκb pages 1-2)

Accordingly, current understanding supported by these sources is:
- **Akirin family**: transcriptional selectivity in NF-κB programs via chromatin remodeler recruitment. (bonnay2014akirinspecifiesnfκb pages 1-2, bonnay2014akirinspecifiesnfκb pages 3-5)
- **AKIRIN1**: well-supported promyogenic regulator; immune-specific roles are plausible by family conservation but less directly established by AKIRIN1-only experiments in the retrieved excerpts. (bosch2020akirinproteinsin pages 3-4)

### 3) Recent developments and latest research (prioritizing 2023–2024)
#### 3.1 2024 human reproductive medicine / embryo outcome association
A 2024 Scientific Reports study analyzed spermatozoal “RNA elements” (REs) from **47** normozoospermic males undergoing fertility treatment with donor oocytes and examined associations between sperm RNA elements and **blastocyst rate**. (https://doi.org/10.1038/s41598-024-60586-6; 2024-05) (hamilton2024acomprehensiveanalysis pages 5-7)

Within this analysis:
- **AKIRIN1** (multiple transcript isoforms) is shown in **Figure 3** with its abundance plotted against **miR-224-5p**; values were normalized as a proportion of the mean abundance per blastocyst-rate group relative to the overall mean across samples to allow comparison between gene and miRNA patterns. (hamilton2024acomprehensiveanalysis pages 5-7)
- AKIRIN1 is described as following a **“down-same”** pattern relative to blastocyst-rate groups (a pattern class defined by the authors for RE abundance trends). (hamilton2024acomprehensiveanalysis pages 4-5)
- In the excerpted pages, AKIRIN1 is also listed among RE-RNAs overlapping with enriched miRNA targets in their TargetScan/miRTarBase overlap analyses (Table 4 context), but the excerpt does not provide a gene-specific correlation coefficient or effect size for AKIRIN1. (hamilton2024acomprehensiveanalysis pages 5-7, hamilton2024acomprehensiveanalysis pages 4-5)

Interpretation: this is *association-level* human evidence placing AKIRIN1 within a sperm RNA signature related to embryo development outcomes and linked to miR-224-5p patterns. It does not, by itself, establish mechanism, but it provides a concrete 2024 human context and motivates follow-up functional studies. (hamilton2024acomprehensiveanalysis pages 5-7, hamilton2024acomprehensiveanalysis pages 4-5)

#### 3.2 2024 disease/trait association landscape (Open Targets)
Open Targets lists AKIRIN1 (ENSG00000174574) associations with traits/diseases including **aging** and **atrial fibrillation**, supported by multiple evidence items and literature links (PubMed IDs listed in the Open Targets evidence payload). (OpenTargets Search: -AKIRIN1)

Interpretation: these associations indicate that AKIRIN1 appears in human genetic/biomedical evidence streams for complex traits, but they should be treated as **hypothesis-generating** rather than definitive function proof without mechanism-resolving experiments. (OpenTargets Search: -AKIRIN1)

### 4) Current applications and real-world implementations
#### 4.1 Muscle wasting / glucocorticoid myopathy (preclinical translational logic)
The glucocorticoid–myostatin–AKIRIN1 pathway has practical relevance because glucocorticoid excess and myostatin signaling are clinically relevant in sarcopenia/cachexia contexts. Dong et al. conclude that inhibiting myostatin or increasing AKIRIN1 expression could be therapeutic strategies to improve satellite-cell activation and muscle growth in diseases with increased glucocorticoid production. (dong2013myostatinsuppressionof pages 1-2)

This represents a **preclinical “actionable node”** concept: AKIRIN1 itself is not an enzyme target, but it is a downstream transcriptional effector that could potentially be modulated indirectly (e.g., through upstream myostatin pathway interventions). (dong2013myostatinsuppressionof pages 8-11)

#### 4.2 Potential biomarker context in fertility medicine (2024)
The 2024 sperm RNA element study explicitly positions REs (including AKIRIN1) as a knowledge base that can be leveraged to improve clinical screening in male infertility. AKIRIN1 is present as a gene in their RE–miRNA and blastocyst rate pattern results. (hamilton2024acomprehensiveanalysis pages 5-7, hamilton2024acomprehensiveanalysis pages 4-5)

#### 4.3 Cancer microenvironment (note: 2025, but highly relevant)
Although outside the user’s 2023–2024 priority window, a 2025 Scientific Reports paper provides mechanistic and translationally oriented evidence that **AKIRIN1 is a direct target of miR-224** in lung fibroblasts, and that AKIRIN1 depletion promotes cancer-associated fibroblast activation and increases lung cancer cell migration/invasion in co-culture and in vivo models; it also reports a survival association with low AKIRIN1 in LUAD. (https://doi.org/10.1038/s41598-024-82189-x; 2025-01) (oh2025mir224activatescancerassociated pages 6-7)

This supports a plausible real-world application domain for AKIRIN1: **tumor microenvironment biology and prognostic stratification** (pending further validation). (oh2025mir224activatescancerassociated pages 6-7)

### 5) Expert opinions / authoritative synthesis
A domain-leading review (Bosch et al., 2020) frames Akirin proteins as evolutionarily conserved regulators of gene-expression programs affecting development (brain/limb/muscle), immune responses, and tumorigenesis, emphasizing that despite strong phenotypic evidence, key molecular unknowns remain (e.g., direct DNA binding; structural basis of “bridge” function; post-translational regulation). (https://doi.org/10.1007/s00018-020-03531-w; 2020-05) (bosch2020akirinproteinsin pages 15-15)

In developmental and immunity contexts, primary Drosophila work argues that Akirin-mediated selection of NF-κB target genes via chromatin remodeling could enable **more selective anti-inflammatory interventions** compared with global NF-κB inhibition, because only subsets of NF-κB targets would be affected. (bonnay2014akirinspecifiesnfκb pages 1-2)

### 6) Relevant statistics and data from recent studies (with limitations noted)
- **Human cohort size (fertility study):** 47 sperm samples sequenced, with significant associations between RNA elements and blastocyst rate reported at **padj < 0.05** across the study’s RE analysis; AKIRIN1 appears among REs discussed/visualized and within RE–miRNA overlap results, but the excerpt does not provide an AKIRIN1-specific effect size or correlation coefficient. (hamilton2024acomprehensiveanalysis pages 5-7, hamilton2024acomprehensiveanalysis pages 4-5)
- **Quantitative data availability for AKIRIN1 mechanistic muscle work:** The 2013 muscle study describes statistically significant changes (e.g., Dex/myostatin lowering AKIRIN1; rescue by myostatin inhibition; improved markers with AKIRIN1 overexpression), but the excerpted text provides limited explicit numeric fold-changes (many values are figure-referenced). (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 4-8)
- **Quantitative gene selectivity in akirin/NF-κB Drosophila model:** Relish-dependent induced genes (**170**), Relish+Akirin-dependent subset (**17**), and Akirin-only (**31**) after immune challenge, supporting selector behavior. (bonnay2014akirinspecifiesnfκb pages 1-2)

### 7) Cellular localization and pathways summary (functional annotation statement)
Collectively, the evidence supports the following functional annotation for human AKIRIN1 (Q9H9L7):
- **Primary molecular role:** a **nuclear transcriptional cofactor/adaptor**, lacking catalytic domains, that promotes context-specific gene expression programs—most directly supported in myogenic contexts as a promyogenic regulator. (bosch2020akirinproteinsin pages 1-3, dong2013myostatinsuppressionof pages 1-2)
- **Primary biological process emphasis (best-supported):** skeletal muscle myogenesis and regeneration; AKIRIN1 supports myoblast/satellite cell proliferation and differentiation and is negatively regulated by myostatin under glucocorticoid stress. (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 3-4)
- **Subcellular site of action:** nucleus (promoter/enhancer-linked gene regulation), with some reports of non-nuclear protein but unclear cytoplasmic function. (bosch2020akirinproteinsin pages 4-6)
- **Pathway links:** myostatin/glucocorticoid axis (strong AKIRIN1-specific evidence); NF-κB/chromatin remodeling selectivity (strong akirin-family evidence; more direct for Akirin2 and Drosophila orthologs than for AKIRIN1 alone in the retrieved excerpts). (dong2013myostatinsuppressionof pages 8-11, bonnay2014akirinspecifiesnfκb pages 1-2, bosch2020akirinproteinsin pages 3-4)

### 8) Evidence map table
| Aspect | Key points | Best supporting citations |
|---|---|---|
| Definition / localization | • Human AKIRIN1 corresponds to Akirin-1 (UniProt Q9H9L7), also called Mighty in earlier literature. • Small akirin-family protein (~200 aa; ~20–25 kDa) with conserved N-terminal nuclear localization signal and predominantly nuclear localization. • Lacks recognizable catalytic domains, supporting a non-enzymatic cofactor/adaptor role rather than enzyme or transporter function. | (bosch2020akirinproteinsin pages 1-3, bosch2020akirinproteinsin pages 3-4, bosch2020akirinproteinsin pages 4-6) |
| Molecular mechanism | • Best-supported model is that Akirin proteins act as transcriptional cofactors that bridge sequence-specific regulators to chromatin-remodeling machinery. • Family-level mechanistic work shows recruitment/stabilization of SWI/SNF/BAF complexes at selected promoters and effects on activating histone marks/chromatin accessibility. • For AKIRIN1 specifically, available mammalian evidence supports promyogenic transcriptional regulation, but direct structural mechanism remains less defined than for AKIRIN2. | (bosch2020akirinproteinsin pages 15-15, bosch2020akirinproteinsin pages 7-8, peek2021cellularandmolecular pages 44-49) |
| Key partners / complexes | • Family evidence supports interactions with SWI/SNF/BAF components such as BAF60 isoforms and Brg1-associated remodeling machinery. • In inflammatory transcription, Akirin-family proteins cooperate with NF-κB pathway components including IκBζ and p50-linked transcriptional complexes. • AKIRIN1-specific recent disease-oriented evidence also implicates functional linkage to FOXO3/MuRF1 regulation and direct targeting by miR-224 in fibroblasts. | (bosch2020akirinproteinsin pages 3-4, bosch2020akirinproteinsin pages 7-8, peek2021cellularandmolecular pages 44-49, oh2025mir224activatescancerassociated pages 6-7) |
| Pathways | • Muscle biology: glucocorticoid → myostatin induction → AKIRIN1 suppression is supported in mouse satellite cells/myoblasts. • Family-level immunity/chromatin work links akirins to NF-κB-selective transcription via SWI/SNF remodeling. • Reviews also place AKIRIN1/Akirin family within broader developmental and signaling contexts including myogenesis, inflammatory signaling, and chromatin-dependent gene regulation. | (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 1-2, bonnay2014akirinspecifiesnfκb pages 1-2, bosch2020akirinproteinsin pages 3-4) |
| Phenotypes / biology | • AKIRIN1 is a promyogenic factor: overexpression increases MyoD and myogenin and improves proliferation/differentiation of myoblasts even under dexamethasone stress. • Dex or myostatin lowers AKIRIN1 mRNA/protein, whereas myostatin inhibition restores AKIRIN1 and improves satellite-cell activity, regeneration, and muscle growth. • Akirin1-null mice are reported as viable/outwardly normal, suggesting paralog-specific divergence from the more essential AKIRIN2. | (dong2013myostatinsuppressionof pages 8-11, dong2013myostatinsuppressionof pages 4-8, dong2013myostatinsuppressionof pages 3-4, bosch2020akirinproteinsin pages 1-3) |
| Recent human association evidence (2024) | • In a 2024 human sperm RNA study of 47 idiopathic infertile males, AKIRIN1 RNA elements were among transcripts associated with blastocyst-rate patterns and were plotted against miR-224-5p. • AKIRIN1 was categorized within a “down-same” abundance pattern relative to blastocyst-rate groups and appeared in RE–miRNA overlap analyses, though no AKIRIN1-specific effect size was provided in the excerpt. • Open Targets currently shows modest literature-backed associations for AKIRIN1 with traits/diseases such as aging and atrial fibrillation, but these are association-level rather than mechanism-proving evidence. | (hamilton2024acomprehensiveanalysis pages 5-7, hamilton2024acomprehensiveanalysis pages 4-5, OpenTargets Search: -AKIRIN1) |
| Translational / application notes | • Preclinical muscle studies position AKIRIN1 as a candidate downstream node in glucocorticoid-myostatin muscle wasting and regeneration pathways. • In 2025 human lung-cancer microenvironment work, miR-224 directly targeted AKIRIN1 in fibroblasts, and AKIRIN1 loss promoted pro-metastatic CAF behavior, suggesting biomarker/therapeutic relevance. • Expert reviews emphasize that akirins may offer selective control points for chromatin-coupled transcriptional programs, but direct AKIRIN1-targeted therapies are not yet established. | (dong2013myostatinsuppressionof pages 8-11, oh2025mir224activatescancerassociated pages 6-7, bosch2020akirinproteinsin pages 1-3, bosch2020akirinproteinsin pages 15-15) |


*Table: This table summarizes the main functional annotation points for human/mammalian AKIRIN1, emphasizing its nuclear cofactor role, muscle-related biology, conserved chromatin-remodeling links, and recent human association evidence. It is useful as a compact evidence map connecting core mechanism, biology, and translational relevance.*

### 9) Source URLs and publication dates (most emphasized)
- Bosch PJ et al. **“Akirin proteins in development and disease: critical roles and mechanisms of action”** *Cell Mol Life Sci* (2020-05). https://doi.org/10.1007/s00018-020-03531-w (bosch2020akirinproteinsin pages 1-3)
- Dong Y et al. **“Myostatin Suppression of Akirin1 Mediates Glucocorticoid-Induced Satellite Cell Dysfunction”** *PLoS ONE* (2013-03). https://doi.org/10.1371/journal.pone.0058554 (dong2013myostatinsuppressionof pages 8-11)
- Hamilton M et al. **“A comprehensive analysis of spermatozoal RNA elements in idiopathic infertile males undergoing fertility treatment”** *Scientific Reports* (2024-05). https://doi.org/10.1038/s41598-024-60586-6 (hamilton2024acomprehensiveanalysis pages 5-7)
- Bonnay F et al. **“Akirin specifies NF-κB selectivity of Drosophila innate immune response via chromatin remodeling”** *EMBO J* (2014-09). https://doi.org/10.15252/embj.201488456 (bonnay2014akirinspecifiesnfκb pages 1-2)
- Open Targets Platform: **AKIRIN1** disease/trait associations (accessed via tool output; evidence includes PubMed IDs in payload). https://platform.opentargets.org/ (OpenTargets Search: -AKIRIN1)

### 10) Scope/limitations of this report
Recent (2023–2024) **mechanistic** AKIRIN1-focused primary literature was limited in the retrieved set; the strongest mechanistic AKIRIN1 evidence available here remains anchored in earlier muscle biology studies, while 2024 work is more **association/expression-context** oriented (fertility outcomes; target–disease associations). Therefore, immune/NF-κB mechanistic conclusions are presented primarily as **akirin-family** mechanisms rather than AKIRIN1-exclusive mechanisms unless explicitly supported. (bosch2020akirinproteinsin pages 3-4, bonnay2014akirinspecifiesnfκb pages 1-2)

References

1. (bosch2020akirinproteinsin pages 1-3): Peter J. Bosch, Stacey L. Peek, Sarit Smolikove, and Joshua A. Weiner. Akirin proteins in development and disease: critical roles and mechanisms of action. Cellular and Molecular Life Sciences, 77:4237-4254, May 2020. URL: https://doi.org/10.1007/s00018-020-03531-w, doi:10.1007/s00018-020-03531-w. This article has 26 citations and is from a domain leading peer-reviewed journal.

2. (bosch2020akirinproteinsin pages 3-4): Peter J. Bosch, Stacey L. Peek, Sarit Smolikove, and Joshua A. Weiner. Akirin proteins in development and disease: critical roles and mechanisms of action. Cellular and Molecular Life Sciences, 77:4237-4254, May 2020. URL: https://doi.org/10.1007/s00018-020-03531-w, doi:10.1007/s00018-020-03531-w. This article has 26 citations and is from a domain leading peer-reviewed journal.

3. (bosch2020akirinproteinsin pages 15-15): Peter J. Bosch, Stacey L. Peek, Sarit Smolikove, and Joshua A. Weiner. Akirin proteins in development and disease: critical roles and mechanisms of action. Cellular and Molecular Life Sciences, 77:4237-4254, May 2020. URL: https://doi.org/10.1007/s00018-020-03531-w, doi:10.1007/s00018-020-03531-w. This article has 26 citations and is from a domain leading peer-reviewed journal.

4. (nowak2012akirin pages 1-2): Scott J. Nowak and Mary K. Baylies. Akirin. Bioarchitecture, 2:209-213, Nov 2012. URL: https://doi.org/10.4161/bioa.22907, doi:10.4161/bioa.22907. This article has 26 citations.

5. (bosch2020akirinproteinsin pages 4-6): Peter J. Bosch, Stacey L. Peek, Sarit Smolikove, and Joshua A. Weiner. Akirin proteins in development and disease: critical roles and mechanisms of action. Cellular and Molecular Life Sciences, 77:4237-4254, May 2020. URL: https://doi.org/10.1007/s00018-020-03531-w, doi:10.1007/s00018-020-03531-w. This article has 26 citations and is from a domain leading peer-reviewed journal.

6. (bonnay2014akirinspecifiesnfκb pages 1-2): François Bonnay, Xuan‐Hung Nguyen, Eva Cohen‐Berros, Laurent Troxler, Eric Batsche, Jacques Camonis, Osamu Takeuchi, Jean‐Marc Reichhart, and Nicolas Matt. Akirin specifies nf-κb selectivity of drosophila innate immune response via chromatin remodeling. The EMBO Journal, 33:2349-2362, Sep 2014. URL: https://doi.org/10.15252/embj.201488456, doi:10.15252/embj.201488456. This article has 124 citations.

7. (bonnay2014akirinspecifiesnfκb pages 3-5): François Bonnay, Xuan‐Hung Nguyen, Eva Cohen‐Berros, Laurent Troxler, Eric Batsche, Jacques Camonis, Osamu Takeuchi, Jean‐Marc Reichhart, and Nicolas Matt. Akirin specifies nf-κb selectivity of drosophila innate immune response via chromatin remodeling. The EMBO Journal, 33:2349-2362, Sep 2014. URL: https://doi.org/10.15252/embj.201488456, doi:10.15252/embj.201488456. This article has 124 citations.

8. (bosch2020akirinproteinsin pages 7-8): Peter J. Bosch, Stacey L. Peek, Sarit Smolikove, and Joshua A. Weiner. Akirin proteins in development and disease: critical roles and mechanisms of action. Cellular and Molecular Life Sciences, 77:4237-4254, May 2020. URL: https://doi.org/10.1007/s00018-020-03531-w, doi:10.1007/s00018-020-03531-w. This article has 26 citations and is from a domain leading peer-reviewed journal.

9. (dong2013myostatinsuppressionof pages 1-2): Yanjun Dong, Jenny S. Pan, and Liping Zhang. Myostatin suppression of akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS ONE, 8:e58554, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0058554, doi:10.1371/journal.pone.0058554. This article has 67 citations and is from a peer-reviewed journal.

10. (dong2013myostatinsuppressionof pages 3-4): Yanjun Dong, Jenny S. Pan, and Liping Zhang. Myostatin suppression of akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS ONE, 8:e58554, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0058554, doi:10.1371/journal.pone.0058554. This article has 67 citations and is from a peer-reviewed journal.

11. (dong2013myostatinsuppressionof pages 8-11): Yanjun Dong, Jenny S. Pan, and Liping Zhang. Myostatin suppression of akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS ONE, 8:e58554, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0058554, doi:10.1371/journal.pone.0058554. This article has 67 citations and is from a peer-reviewed journal.

12. (dong2013myostatinsuppressionof pages 4-8): Yanjun Dong, Jenny S. Pan, and Liping Zhang. Myostatin suppression of akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS ONE, 8:e58554, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0058554, doi:10.1371/journal.pone.0058554. This article has 67 citations and is from a peer-reviewed journal.

13. (hamilton2024acomprehensiveanalysis pages 5-7): Matthew Hamilton, Stewart Russell, Grace M. Swanson, Stephen A. Krawetz, Karen Menezes, Sergey I. Moskovtsev, and Clifford Librach. A comprehensive analysis of spermatozoal rna elements in idiopathic infertile males undergoing fertility treatment. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60586-6, doi:10.1038/s41598-024-60586-6. This article has 9 citations and is from a peer-reviewed journal.

14. (hamilton2024acomprehensiveanalysis pages 4-5): Matthew Hamilton, Stewart Russell, Grace M. Swanson, Stephen A. Krawetz, Karen Menezes, Sergey I. Moskovtsev, and Clifford Librach. A comprehensive analysis of spermatozoal rna elements in idiopathic infertile males undergoing fertility treatment. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60586-6, doi:10.1038/s41598-024-60586-6. This article has 9 citations and is from a peer-reviewed journal.

15. (OpenTargets Search: -AKIRIN1): Open Targets Query (-AKIRIN1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

16. (oh2025mir224activatescancerassociated pages 6-7): Seonyeong Oh, Sieun Lee, Inyoung Cheon, and Young-Ho Ahn. Mir-224 activates cancer-associated fibroblasts to enhance lung cancer cell migration and invasion by targeting akirin1. Scientific Reports, Jan 2025. URL: https://doi.org/10.1038/s41598-024-82189-x, doi:10.1038/s41598-024-82189-x. This article has 5 citations and is from a peer-reviewed journal.

17. (peek2021cellularandmolecular pages 44-49): Cellular and molecular mechanisms of Akirin2 function in maturing neurons

## Artifacts

- [Edison artifact artifact-00](AKIRIN1-deep-research-falcon_artifacts/artifact-00.md)

## Citations

1. bosch2020akirinproteinsin pages 1-3
2. nowak2012akirin pages 1-2
3. bosch2020akirinproteinsin pages 4-6
4. dong2013myostatinsuppressionof pages 8-11
5. bosch2020akirinproteinsin pages 3-4
6. hamilton2024acomprehensiveanalysis pages 5-7
7. hamilton2024acomprehensiveanalysis pages 4-5
8. dong2013myostatinsuppressionof pages 1-2
9. bosch2020akirinproteinsin pages 15-15
10. bosch2020akirinproteinsin pages 7-8
11. dong2013myostatinsuppressionof pages 3-4
12. dong2013myostatinsuppressionof pages 4-8
13. peek2021cellularandmolecular pages 44-49
14. https://doi.org/10.1007/s00018-020-03531-w;
15. https://doi.org/10.4161/bioa.22907;
16. https://doi.org/10.15252/embj.201488456;
17. https://doi.org/10.1371/journal.pone.0058554;
18. https://doi.org/10.1038/s41598-024-60586-6;
19. https://doi.org/10.1038/s41598-024-82189-x;
20. https://doi.org/10.1007/s00018-020-03531-w
21. https://doi.org/10.1371/journal.pone.0058554
22. https://doi.org/10.1038/s41598-024-60586-6
23. https://doi.org/10.15252/embj.201488456
24. https://platform.opentargets.org/
25. https://doi.org/10.1007/s00018-020-03531-w,
26. https://doi.org/10.4161/bioa.22907,
27. https://doi.org/10.15252/embj.201488456,
28. https://doi.org/10.1371/journal.pone.0058554,
29. https://doi.org/10.1038/s41598-024-60586-6,
30. https://doi.org/10.1038/s41598-024-82189-x,